Citadel Advisors LLC Takes $1.34 Million Position in Greenland Mines Ltd. Common Stock $GRML

Citadel Advisors LLC purchased a new stake in Greenland Mines Ltd. Common Stock (NASDAQ:GRML) during the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 5,165,648 shares of the company’s stock, valued at approximately $1,343,000. Citadel Advisors LLC owned about 1.63% of Greenland Mines Ltd. Common Stock at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of GRML. Jane Street Group LLC bought a new stake in Greenland Mines Ltd. Common Stock in the 2nd quarter valued at about $26,000. XTX Topco Ltd grew its position in shares of Greenland Mines Ltd. Common Stock by 101.2% during the 4th quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock worth $46,000 after purchasing an additional 80,768 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Greenland Mines Ltd. Common Stock during the fourth quarter worth approximately $126,000. Finally, Geode Capital Management LLC increased its holdings in shares of Greenland Mines Ltd. Common Stock by 51.8% during the fourth quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock worth $142,000 after purchasing an additional 167,905 shares during the period. Institutional investors and hedge funds own 20.07% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on GRML. Wall Street Zen upgraded Greenland Mines Ltd. Common Stock to a “sell” rating in a research note on Saturday, August 29th. Weiss Ratings upgraded Greenland Mines Ltd. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 25th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Insider Buying and Selling

In other news, Director Jason David Sawyer purchased 4,800 shares of the business’s stock in a transaction dated Wednesday, July 22nd. The shares were purchased at an average cost of $11.50 per share, with a total value of $55,200.00. Following the completion of the purchase, the director owned 4,800 shares of the company’s stock, valued at $55,200. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Jeff Leblanc purchased 14,000 shares of Greenland Mines Ltd. Common Stock stock in a transaction dated Tuesday, August 25th. The shares were purchased at an average price of $9.72 per share, for a total transaction of $136,080.00. Following the completion of the acquisition, the chief financial officer owned 110,406 shares of the company’s stock, valued at approximately $1,073,146.32. The trade was a 14.52% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 11.30% of the stock is currently owned by corporate insiders.

Greenland Mines Ltd. Common Stock Price Performance

Shares of Greenland Mines Ltd. Common Stock stock opened at $4.19 on Thursday. The company’s 50 day moving average price is $8.99 and its two-hundred day moving average price is $17.04. The firm has a market capitalization of $13.32 million, a P/E ratio of -0.36 and a beta of 6.91. Greenland Mines Ltd. Common Stock has a fifty-two week low of $4.15 and a fifty-two week high of $36.99.

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) last announced its quarterly earnings results on Monday, August 17th. The company reported ($0.03) EPS for the quarter.

Greenland Mines Ltd. Common Stock Company Profile

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.